TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19930696

Group type: EXPERIMENTAL
Intervention: HRQOL assessed using the 36-item Short-Form health survey (SF36) in CKD patients
Number of subjects: 944

Group type: COMPARATOR
Intervention: Cumulative survival rate based on SF36 scores
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: SF36 score (physical and mental components)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Physical components of SF36
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Mental components of SF36
Number of subjects: 944
Study: 17586189

Group type: EXPERIMENTAL
Intervention: DTaP-HepB-IPV plus PCV-7 and Hib
Number of subjects: 199

Group type: COMPARATOR
Intervention: Separate vaccines
Number of subjects: 199

Group type: COMPARATOR
Intervention: DTaP-HepB-IPV plus Hib with PCV-7 administered 2 weeks later
Number of subjects: 199
Study: 15473622

Group type: EXPERIMENTAL
Intervention: Group II (BM) - hyperbaric bupivacaine 0.5% 2 mL + 1 mL of 2mg preservative‐free midazolam
Number of subjects: 44

Group type: COMPARATOR
Intervention: Group I (B) - hyperbaric bupivacaine 0.5% 2 mL + saline 0.9% 1 mL
Number of subjects: 44
Study: 11303198

Group type: EXPERIMENTAL
Intervention: 1 mg micronized 17 beta‐estradiol daily sequentially combined with 5 or 10 mg dydrogesterone for 14 days of each 28‐day cycle during 12 months and thereafter 2 mg 17 beta‐estradiol combined with 10 mg dydrogesterone for a period of 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 9627593

Group type: EXPERIMENTAL
Intervention: Milk formula (MF; 67 cal/100 ml)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Yogurt formula (YF; prepared from the same milk formula)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Milk formula (MF)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Yogurt formula (YF)
Number of subjects: 96
Study: 8154907

Group type: EXPERIMENTAL
Intervention: Mature donor breast milk
Number of subjects: 502

Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 502

Group type: COMPARATOR
Intervention: Standard term formula
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Donor breast milk
Number of subjects: 502
Study: 3282034

Group type: EXPERIMENTAL
Intervention: BW942C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30627989

Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner (DJBL)
Number of subjects: 29
Study: 28569520

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) focused on early change
Number of subjects: 44

Group type: COMPARATOR
Intervention: Motivational Interviewing (MI)
Number of subjects: 44
Study: 25908506

Group type: EXPERIMENTAL
Intervention: Weight-loss intervention + 2000 IU/day oral vitamin D3
Number of subjects: 218

Group type: COMPARATOR
Intervention: Weight-loss intervention + daily placebo
Number of subjects: 218
Study: 22682669

Group type: EXPERIMENTAL
Intervention: Erlotinib-first strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy-first strategy
Number of subjects: 0
Study: 22436774

Group type: EXPERIMENTAL
Intervention: Talon (n = 28)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wires only (control, n = 23)
Number of subjects: 51
Study: 20048519

Group type: EXPERIMENTAL
Intervention: T-bow training program for lower limbs (8 weeks, 5 exercises: squat, lateral and frontal swings, lunges, plantarflexions)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 16750455

Group type: EXPERIMENTAL
Intervention: MAS XR 30 mg/d
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: MAS XR 40 mg/d
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: MAS XR
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 14729287

Group type: EXPERIMENTAL
Intervention: High monitors receiving extensive information
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Low monitors receiving minimal information
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard care (usual information plus coaching by a nurse)
Number of subjects: 260
Study: 11726729

Group type: EXPERIMENTAL
Intervention: Ventilated newborns without hypocapnia
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Ventilated newborns with hypocapnia
Number of subjects: 777

Group type: COMPARATOR
Intervention: Unventilated newborns
Number of subjects: 777
Study: 9416933

Group type: EXPERIMENTAL
Intervention: Extended-release isosorbide mononitrate (ER-ISMN) 60 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Extended-release isosorbide mononitrate (ER-ISMN) 120 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 8279667

Group type: EXPERIMENTAL
Intervention: Alcohol administration (exact dosage not specified)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no alcohol, exact dosage not specified)
Number of subjects: 82
Study: 3300945

Group type: EXPERIMENTAL
Intervention: Peptichemio (1.2 mg/kg/d) for two 5-day courses; Group 2
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Radiotherapy to the tumor bed; Group 2 (children older than 1 year)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No radiotherapy; Group 2 (children older than 1 year)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Complete tumor resection; Group 1
Number of subjects: 65

Group type: COMPARATOR
Intervention: No further antitumor therapy; Group 1
Number of subjects: 65
Study: 28851121

Group type: EXPERIMENTAL
Intervention: External Facilitation (EF)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Educational Outreach Visits (EOV)
Number of subjects: 2
Study: 28586623

Group type: EXPERIMENTAL
Intervention: Follow-up survey measuring vaccine hesitancy scores
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Follow-up survey measuring the proportion of vaccine hesitant mothers
Number of subjects: 237
Study: 25534635

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization plus RF ablation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization plus MW ablation
Number of subjects: 89
Study: 24024771

Group type: EXPERIMENTAL
Intervention: Standard calorie‐ and fat‐restricted diet (STD‐D)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Calorie‐ and fat‐restricted lacto‐ovo‐vegetarian diet (LOV‐D)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Weight loss
Number of subjects: 143
Study: 19577829

Group type: EXPERIMENTAL
Intervention: Foot reflexology (30-minute session for five consecutive days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (received the same care without reflexology therapy)
Number of subjects: 65
Study: 17451581

Group type: EXPERIMENTAL
Intervention: Curettage plus cryosurgery (C&C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical excision (SE)
Number of subjects: 100
Study: 14984323

Group type: EXPERIMENTAL
Intervention: Octreotide (150 microg subcutaneously for two weeks)
Number of subjects: 0
Study: 11794149

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Enoxaparin 30 mg twice daily
Number of subjects: 1049
Study: 9677602

Group type: EXPERIMENTAL
Intervention: Acute asthma
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Stable asthma
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acute bronchiolitis
Number of subjects: 39

Group type: COMPARATOR
Intervention: Controls (non-atopic)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RSV positive and RSV negative bronchiolitis
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: sE‐selectin and sP‐selectin
Number of subjects: 39
Study: 7988251

Group type: EXPERIMENTAL
Intervention: Immediate combination chemotherapy (CAP)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Delayed combination chemotherapy (CAP)
Number of subjects: 188
Study: 2729939

Group type: EXPERIMENTAL
Intervention: Oral antacid (30 ml of aluminum hydroxide orally four times a day for 4 days)
Number of subjects: 6
Study: 31386758

Group type: EXPERIMENTAL
Intervention: C8-silk lipoamino acid functionalized pigments (FA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pure pigments (FP)
Number of subjects: 40
Study: 30442233

Group type: EXPERIMENTAL
Intervention: Diet/Ca/D (cholecalciferol 50,000 IU/subject/week and calcium 1200 mg/dL/subject/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diet/Ca (calcium 1200 mg/dL/subject/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: CON (no prescribed supplements)
Number of subjects: 45
Study: 25713312

Group type: EXPERIMENTAL
Intervention: Streaming video of antitobacco ads
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Screenshot of antitobacco ads
Number of subjects: 1034
Study: 24648723

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No fluoxetine (control group, n=25)
Number of subjects: 50
Study: 22198621

Group type: EXPERIMENTAL
Intervention: Black tea infusate (3 x 200 ml/day for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hot water (equivalent volume for same intervention period)
Number of subjects: 100
Study: 20515467

Group type: EXPERIMENTAL
Intervention: Intravenous rehydration (IVR)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Nasogastric rehydration (NGR)
Number of subjects: 750
Study: 18076246

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16146476

Group type: EXPERIMENTAL
Intervention: diclofenac 50 mg x 3
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 12866828

Group type: EXPERIMENTAL
Intervention: Visual discrimination tasks with increasing complexity
Number of subjects: 28

Group type: COMPARATOR
Intervention: Auditory processing tasks (control)
Number of subjects: 28
Study: 10393606

Group type: EXPERIMENTAL
Intervention: Beclomethasone therapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 8930940

Group type: EXPERIMENTAL
Intervention: hGAL (80 pmol/kg/min for 60 minutes)
Number of subjects: 9

Group type: COMPARATOR
Intervention: PD (120 mg orally)
Number of subjects: 9

Group type: COMPARATOR
Intervention: PD and hGAL
Number of subjects: 9
Study: 2034826

Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution (15 ml/kg body weight) with lumbar epidural anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (epidural anesthesia only, no hemodilution)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution
Number of subjects: 30
Study: 6132819

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 8
Study: 30630342

Group type: EXPERIMENTAL
Intervention: Messages encouraging influenza vaccination via e‐mails, texts, and postal mail
Number of subjects: 25649

Group type: COMPARATOR
Intervention: Messages encouraging influenza vaccination via e‐mails and texts
Number of subjects: 25649

Group type: COMPARATOR
Intervention: No messages
Number of subjects: 25649
Study: 28715554

Group type: EXPERIMENTAL
Intervention: Prosodic variation during ultrasound visual feedback training
Number of subjects: 6

Group type: COMPARATOR
Intervention: No prosodic variation during ultrasound visual feedback training
Number of subjects: 6
Study: 26525065

Group type: EXPERIMENTAL
Intervention: Comprehensive personalized method for cardiovascular prevention
Number of subjects: 12513

Group type: EXPERIMENTAL
Intervention: Improvement in global cardiovascular risk profile during the first year
Number of subjects: 12513
Study: 24501384

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG), once daily for 4 weeks
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 21963389

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (2×100 ml/d for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (2×100 ml/d for 8 weeks)
Number of subjects: 30
Study: 19362675

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous infusion)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Risedronate (5 mg oral daily)
Number of subjects: 833
Study: 17239114

Group type: EXPERIMENTAL
Intervention: Esophageal cooling (ECO) using a cooled water-irrigated intraesophageal balloon (IB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no esophageal cooling)
Number of subjects: 8
Study: 16339095

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg or 10 mg)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 11960396

Group type: EXPERIMENTAL
Intervention: All trans retinoic acid (ATRA) 45 mg/m²/day from day 1 to complete remission combined with Idarubicin 10 mg/m²/day for 3 days and cytarabine 1000 mg/m²/12 h for 6 days.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Idarubicin 10 mg/m²/day for 3 days and cytarabine 1000 mg/m²/12 h for 6 days without ATRA.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: ATRA combined with chemotherapy (Idarubicin and Cytarabine).
Number of subjects: 95
Study: 10190855

Group type: EXPERIMENTAL
Intervention: CD pedicle screw implants
Number of subjects: 61

Group type: COMPARATOR
Intervention: Posterolateral fusions alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Osteoblast proliferation (excellent, good, poor)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Age influence on osteoblast proliferation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Preoperative tobacco smoking
Number of subjects: 61
Study: 7577781

Group type: COMPARATOR
Intervention: Blind standard technique (group A: 8 mL bupivacaine 0.25%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ultrasonographic imaging technique (group B: 5 mL bupivacaine 0.25%)
Number of subjects: 12
Study: 2034479

Group type: EXPERIMENTAL
Intervention: HiFe (13.8 mg elemental iron)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: MidFe (7 mg elemental iron)
Number of subjects: 55

Group type: COMPARATOR
Intervention: NatFe (no elemental iron)
Number of subjects: 55
Study: 7326166

Group type: EXPERIMENTAL
Intervention: L(+) mepivacaine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: D(‐) mepivacaine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Racemic mepivacaine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: L(+) and D(‐) mepivacaine
Number of subjects: 23
Study: 31907024

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and cognitive training (ACT)
Number of subjects: 120
Study: 30616692

Group type: EXPERIMENTAL
Intervention: CSNAT-Stroke intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 28837598

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 27266853

Group type: EXPERIMENTAL
Intervention: Favorable diuretic response and hemoconcentration in PROTECT trial
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Favorable diuretic response and hemoconcentration in EVEREST trial
Number of subjects: 1180
Study: 23557627

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg bid for 10 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20499072

Group type: EXPERIMENTAL
Intervention: Calorie‐restricted legume‐based diet (L‐diet)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calorie‐restricted legume-free diet (C‐diet)
Number of subjects: 30
Study: 18282237

Group type: EXPERIMENTAL
Intervention: Community-wide azithromycin treatment
Number of subjects: 1722
Study: 16531164

Group type: EXPERIMENTAL
Intervention: Biphasic OC containing 40/30 mug ethynylestradiol (EE)+25/125 mug desogestrel (DSG; n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Monophasic OC containing 35 mug EE and 2 mg cyproterone acetate (CPA; n=10)
Number of subjects: 20
Study: 12697594

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intrathecal morphine 0.05 mg
Number of subjects: 6
Study: 10895744

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine with fentanyl 1 microgram ml‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.2% ropivacaine with fentanyl 2 micrograms ml‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PCEA ropivacaine with fentanyl
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-concentration/high-volume solution
Number of subjects: 40
Study: 9561637

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation for 12 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Weekly iron supplementation for 12 weeks
Number of subjects: 144
Study: 1532940

Group type: EXPERIMENTAL
Intervention: Domiciliary nebulized fenoterol (F) 1.25 mg and ipratropium (I) 0.5 mg for three weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Usual therapy
Number of subjects: 20
Study: 3157576

Group type: EXPERIMENTAL
Intervention: Zimeldine (200 mg/day, increased to 300 mg/day after 7 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31779624

Group type: EXPERIMENTAL
Intervention: RESPOND intervention
Number of subjects: 263

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 263
Study: 28251784

Group type: EXPERIMENTAL
Intervention: Blood flow-restricted exercise at 10% AOP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood flow-restricted exercise at 90% AOP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood flow-restricted exercise at various pressures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood flow-restricted exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common BFR protocol with 30% 1RM
Number of subjects: 0
Study: 27746838

Group type: EXPERIMENTAL
Intervention: Canalith Repositioning Maneuver and Vestibular Rehabilitation for 13 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Canalith Repositioning Maneuver
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Canalith Repositioning Maneuver and Vestibular Rehabilitation
Number of subjects: 14
Study: 24590620

Group type: EXPERIMENTAL
Intervention: Denture cleanser immersion for 3 min/day for seven consecutive days
Number of subjects: 2

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 2
Study: 22503790

Group type: EXPERIMENTAL
Intervention: Painful stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-painful stimulation
Number of subjects: 0
Study: 20470226

Group type: EXPERIMENTAL
Intervention: Diabetes-specific enteral formula
Number of subjects: 22
Study: 18407382

Group type: EXPERIMENTAL
Intervention: AS‐H5N1 vaccine
Number of subjects: 5071

Group type: COMPARATOR
Intervention: Fluarix (licensed seasonal influenza vaccine)
Number of subjects: 5071
Study: 17569261

Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 250
Study: 15206667

Group type: EXPERIMENTAL
Intervention: Olanzapine at >16 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone at 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone at 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone at 2 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine at 6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole at 10 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine above 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol at 3.3 to 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: High doses of haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: High doses of FGAs
Number of subjects: 0
Study: 11388531

Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (15 ml; 2%) with intravenous saline placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous lidocaine (1 mg/kg bolus dose; 25 microg x kg(‐1) x min(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anesthesia alone (intravenous saline placebo)
Number of subjects: 30
Study: 9253321

Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HRT+D (HRT + vitamin D3, 300 IU/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: D (vitamin D3, 300 IU/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (calcium lactate, 500 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: D group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HRT and HRT+D groups
Number of subjects: 72
Study: 8390368

Group type: EXPERIMENTAL
Intervention: metoclopramide 20 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: ondansetron 8 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: granisetron 3 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: saline 20 ml
Number of subjects: 9
Study: 3829698

Group type: EXPERIMENTAL
Intervention: Mechanical debridement plus IDU
Number of subjects: 5

Group type: COMPARATOR
Intervention: IDU alone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of PTGG and steroid subconjunctival injection
Number of subjects: 5

Group type: COMPARATOR
Intervention: Steroid subconjunctival injection alone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of PTGG alone
Number of subjects: 5
Study: 30758745

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 310

Group type: COMPARATOR
Intervention: Inotuzumab Ozogamicin (InO)
Number of subjects: 310